Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy

Journal of Clinical Investigation

Volumn 122, Issue 6, 2012, Pages 2141-2152

  Sauer, Aisha V ^a,b   Morbach, Henner ^b   Brigida, Immacolata ^a   Ng, Yen Shing ^b   Aiuti, Alessandro ^a,c   Meffre, Eric ^b  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR;

ADENOSINE DEAMINASE DEFICIENCY; ARTICLE; B LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SEVERE COMBINED IMMUNODEFICIENCY; TRANSITIONAL CELL CARCINOMA;

ADENOSINE DEAMINASE; ADULT; ANTIBODIES, ANTINUCLEAR; B-LYMPHOCYTES; FEMALE; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, B-CELL; RECEPTORS, ANTIGEN, T-CELL; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84861833417     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61788     Document Type: Article

References (48)

1. Hirschhorn R, Candotti F. Immunodeficiency due to defects of purine metabolism In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases. Oxford, United Kingdom: Oxford University Press; 2006:169-196.
2. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009;114(17):3524-3532.
3. Aiuti A, et al. Long-term safety and efficacy of gene therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency. New Engl J Med. 2009;360(5):447-458.
4. Gaspar HB, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80.
5. Aiuti A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8(5):423-425. (Pubitemid 34546725)
6. Ferrua F, Brigida I, Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr Opin Allergy Clin Immunol. 2010;10(6):551-556.
7. Notarangelo LD, et al. Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency. Eur J Pediatr. 1992;151(11):811-814.
8. Ozsahin H, et al. Adenosine deaminase deficiency in adults. Blood. 1997;89(8):2849-2855. (Pubitemid 27172571)
9. Malacarne F, et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol. 2005;35(11):3376-3386. (Pubitemid 41672541)
10. Serana F, et al. The different extent of B and T cell immune reconstitution after hematopoietic stem cell transplantation and enzyme replacement therapies in SCID patients with adenosine deaminase deficiency. J Immunol. 2010;185(12):7713-7722.
11. Mazzolari E, et al. Single-center analysis of longterm outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency. Immunol Res. 2009;44(1-3):4-17.
12. Neven B, et al. Long-term outcome after haematopoietic stem cell transplantation of a single-centre cohort of 90 patients with severe combined immunodeficiency: Long-term outcome of HSCT in SCID. Blood. 2009;113(17):4114- 4124.
13. Sauer AV, Aiuti A. New insights into the pathogenesis of adenosine deaminase-severe combined immunodeficiency and progress in gene therapy. Curr Opin Allergy Clin Immunol. 2009;9(6):496-502.
14. Chan B, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117(2):133-143. (Pubitemid 41407723)
15. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301(5638):1374-1377. (Pubitemid 37075812)
16. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A. 1996;93(6):2264-2271. (Pubitemid 26104339)
17. Nemazee D, et al. B-cell-receptor-dependent positive and negative selection in immature B cells. Curr Top Microbiol Immunol. 2000;245(2):57-71.
18. Cancro MP. Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol. 2009;9(9):657-661.
19. Grimaldi CM, Hicks R, Diamond B. B cell selection and susceptibility to autoimmunity. J Immunol. 2005;174(4):1775-1781. (Pubitemid 40223915)
20. Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997;90(6):1073-1083. (Pubitemid 27408521)
21. Menard L, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest. 2011;121(9):3635-3644.
22. Ng YS, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E. Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med. 2004;200(7):927-934. (Pubitemid 39362928)
23. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823-835. (Pubitemid 44631651)
24. Isnardi I, et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity. 2008;29(5):746-757.
25. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest. 2001;108(1):131-141. (Pubitemid 32634930)
26. Power Coombs MR, Belderbos ME, Gallington LC, Bont L, Levy O. Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities. Expert Rev Anti Infect Ther. 2011;9(2):261-269.
27. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol. 2010;162(2):271-279.
28. Cassani B, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood. 2008;111(8):4209- 4219.
29. Minguet S, Huber M, Rosenkranz L, Schamel WW, Reth M, Brummer T. Adenosine and cAMP are potent inhibitors of the NF-kappa B pathway downstream of immunoreceptors. Eur J Immunol. 2005;35(1):31-41. (Pubitemid 40123849)
30. Herve M, et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med. 2007;204(7):1583-1593. (Pubitemid 47048025)
31. Radic MZ, Mackle J, Erikson J, Mol C, Anderson WF, Weigert M. Residues that mediate DNA binding of autoimmune antibodies. J Immunol. 1993;150(11):4966-4977. (Pubitemid 23150364)
32. Menard L, Samuels J, Ng YS, Meffre E. Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis. Arthritis Rheum. 2011;63(5):1237-1245.
33. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med. 2006;203(2):393-400. (Pubitemid 43290848)
34. Bradwell AR. IgG subclasses in childhood infections. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1995;36(3):164-169.
35. Hershfield M. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol. 2005;35(1):25-30. (Pubitemid 40123848)
36. Samet MK. Inhibition of antibody production by 2-chloroadenosine. Life Sci. 1985;37(3):225-233. (Pubitemid 15060107)
37. Klonowski KD, Primiano LL, Monestier M. Atypical VH-D-JH rearrangements in newborn autoimmune MRL mice. J Immunol. 1999;162(3):1566-1572. (Pubitemid 29307030)
38. Aldrich MB, Chen W, Blackburn MR, Martinez-Valdez H, Datta SK, Kellems RE. Impaired germinal center maturation in adenosine deaminase deficiency. J Immunol. 2003;171(10):5562-5570. (Pubitemid 37432847)
39. Arechiga AF, et al. Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. J Immunol. 2009;182(6):3343-3347.
40. Vang T, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet. 2005;37(12):1317-1319. (Pubitemid 41722185)
41. Meyers G, et al. Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proc Natl Acad Sci U S A. 2011;108(28):11554- 11559.
42. Sauer AV, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012;119(6):1428-1439.
43. Cassani B, et al. Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J Exp Med. 2010;207(7):1525-1540.
44. Booth C, Gaspar HB. Pegademase bovine (PEGADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics. 2009;3:349-358.
45. Ochs HD, et al. Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood. 1992;80(5):1163-1171.
46. Mortellaro A, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood. 2006;108(9):2979-2988.
47. Meffre E, Schaefer A, Wardemann H, Wilson P, Davis E, Nussenzweig MC. Surrogate light chain expressing human peripheral B cells produce selfreactive antibodies. J Exp Med. 2004;199(1):145-150. (Pubitemid 38076487)
48. Sauer AV, et al. ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency. Blood. 2009;114(15):3216-3226.